The JV, registered in Kuwait as Avita Medical Mena (AVM), will be 70% controlled by Avita Medical.
AVM will be responsible for sales and marketing efforts in the countries of Egypt, Iraq, Jordan, Kuwait, Lebanon, Iran, Syria, Saudi Arabia, Bahrain, Oman, Yemen, UAE and Qatar.
The company expects to launch the product on 24 September 2011.
ReCell allows in theater preparation of a spray on suspension consisting of cells derived from a small, thin biopsy of a patient’s own skin that is sufficient to cover an area up to 80 times the size of the biopsy